CAMBRIDGE BIOTECH NAMES ALISON TAUNTON-RIGBY, PH.D., PRESIDENT AND CEOWORCESTER, Mass., April 7 /PRNewswire/ -- Alison Taunton-Rigby, Ph.D., has been elected president, chief executive officer and a director of Cambridge Biotech Corp., the company announced today. Dr. Taunton-Rigby has over 20 years of experience as a senior executive in the biotechnology industry."Alison's decision to join Cambridge Biotech is a significant endorsement of the turnaround potential of the company," said John S. Scott, chairman emeritus of Cambridge Biotech Corp. "Her leadership skills and biotechnology business experience will be essential as Cambridge Biotech continues to reorganize in order to move the company forward." Two other senior management changes were announced in conjunction with Dr. Taunton-Rigby's appointment. John S. Scott has stepped down as chairman, remaining as director and chairman emeritus, and Jeffrey T. Beaver, who has been serving as president and interim CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , has been named chairman of the board. Previously, Dr. Taunton-Rigby was president and CEO of Mitotix, Inc., a privately held biotechnology company located in Cambridge, Massachusetts. Before joining Mitotix, Dr. Taunton-Rigby was senior vice president, biotherapeutics, of Genzyme Corporation where she had overall responsibility for Genzyme's biotherapeutic business and the development of Ceredase(R), Genzyme's lead product for the treatment of Gaucher's disease. Prior to Genzyme, she held senior management positions at Vivotech, Biogen, Inc., Collaborative Research, Inc. and Arthur D. Little Arthur D. Little, Inc. is the world's first management consulting firm. Founded in 1886 by Arthur Dehon Little, an MIT chemist who discovered acetate, and co-worker Roger Griffin, in Cambridge, Massachusetts, Arthur D. Little pioneered the concept of contracted technology research. . In addition, Dr. Taunton-Rigby is president of the Massachusetts Biotechnology Council. She is also a director of Synaptic Pharmaceutical Corp. and of the CML 1. CML - A query language. ["Towards a Knowledge Description Language", A. Borgida et al, in On Knowledge Base Management Systems, J. Mylopoulos et al eds, Springer 1986]. 2. CML - Concurrent ML. Group, a trustee of the Worcester Foundation for Experimental Biology, and a member of Bentley College Ethics Advisory Board. Dr. Taunton-Rigby received her Ph.D. and B.Sc. degrees in Chemistry from the University of Bristol in England and is a graduate of the Advanced Management Program of the Harvard Business School Harvard Business School, officially named the Harvard Business School: George F. Baker Foundation, and also known as HBS, is one of the graduate schools of Harvard University. . Cambridge Biotech Corporation, which filed for protection under Chapter 11 of the U.S. Bankruptcy Code on July 7, 1994, is a therapeutics and diagnostics company involved in developing vaccines, adjuvants and diagnostics for treating cancer and infectious diseases in humans and animals.
-0- 4/7/95
/CONTACT: Karen Meenan, Associate General Counsel of Cambridge Biotech Corp., 508-797-5777, ext. 523, or Jeanine Kelly of Feinstein Partners Inc., 617-577-8110/ CO: Cambridge Biotech Corp. ST: Massachusetts IN: MTC mtc - A Modula-2 to C translator. ftp://rusmv1.rus.uni-stuttgart.de/soft/Unixtools/compilerbau/mtc.tar.Z. SU: PER DP -- NE018 -- 5451 04/07/95 15:00 EDT |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion